Figure 2. Circular RNAs with efficacy in AML-related preclinical in vivo systems. A) Up-regulated circular RNAs. B) Down-regulated circular RNAs. circDLEU2: circ deleted in lymphocytic leukemia 2; circMYBL2: circMYB proto-oncogene like 2; circZBTB46: circ zinc finger and BTB domain containing 46; circTAP1: circ threonine-aspartase 1; FLT3: fms-like tyrosine kinase 3; FLT-ITD: fms-like tyrosine kinase internal duplication domain; KIT: receptor tyrosine kinase KIT; HMGA2: high-mobility group A2; miR: microRNA; NR: not resolved; PLXNB2: plexin B2; PTBP1: polypyrimidine tract binding protein1; PTEN: phosphatase and tensin homolog; PRKACB: cAMP-dependent protein kinase A catalytic subunit β; RUNX3: runt-related transcription factor 3; SCD: stearoyl-CoA-desaturase; TG: tumor growth; YWHAZ: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta.